Catriona Yale Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $39.30, for a total value of $393,000.00. Following the completion of the sale, the insider now owns 95,034 shares in the company, valued at $3,734,836.20. The trade was a 9.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Tuesday, April 15th, Catriona Yale sold 9,073 shares of Akero Therapeutics stock. The shares were sold at an average price of $37.91, for a total value of $343,957.43.
• On Monday, March 17th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.76, for a total value of $447,600.00.
• On Wednesday, March 12th, Catriona Yale sold 614 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.88, for a total value of $27,556.32.
• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $49.87, for a total value of $498,700.00.

Akero Therapeutics Stock Down 1.9%

Shares of NASDAQ:AKRO traded down $0.73 during trading on Monday, reaching $38.14. 740,553 shares of the stock were exchanged, compared to its average volume of 911,058. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a 1-year low of $17.86 and a 1-year high of $58.40. The stock has a fifty day moving average of $40.85 and a two-hundred day moving average of $37.88. The firm has a market cap of $3.04 billion, a price-to-earnings ratio of -10.17 and a beta of -0.12.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Monday, May 12th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.01) by $1.91. Research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Akero Therapeutics

A number of institutional investors have recently modified their holdings of AKRO. Barclays PLC raised its position in shares of Akero Therapeutics by 127.9% during the third quarter. Barclays PLC now owns 127,668 shares of the company’s stock worth $3,662,000 after purchasing an additional 71,652 shares during the period. SG Americas Securities LLC raised its position in shares of Akero Therapeutics by 4,022.1% during the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock worth $16,636,000 after purchasing an additional 583,486 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Akero Therapeutics by 10.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,800 shares of the company’s stock worth $412,000 after purchasing an additional 1,446 shares during the period. abrdn plc raised its position in shares of Akero Therapeutics by 118.7% during the fourth quarter. abrdn plc now owns 269,782 shares of the company’s stock worth $7,505,000 after purchasing an additional 146,424 shares during the period. Finally, Rhumbline Advisers raised its position in shares of Akero Therapeutics by 1.3% during the fourth quarter. Rhumbline Advisers now owns 105,686 shares of the company’s stock worth $2,940,000 after purchasing an additional 1,310 shares during the period.

Analyst Ratings Changes

AKRO has been the topic of several analyst reports. HC Wainwright upped their target price on Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a report on Monday, March 3rd. Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Citigroup dropped their price target on Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. UBS Group boosted their price target on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Finally, Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Akero Therapeutics has a consensus rating of “Buy” and a consensus price target of $82.33.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.